Most of the NCOR1 mutations in the ICI-treated and TCGA-BLCA cohorts were missense mutations (50.0 and 61.0%), nonsense mutations (27.8 and 22.0%) and frameshift mutations (22.2 and 12.2%). The gene discussed is NCOR1; the disease is bladder transitional cell carcinoma.